May 21, 2020
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
May 07, 2020
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
Mar 03, 2020
Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update
Jan 10, 2020
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Nov 07, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
May 06, 2019
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
Mar 20, 2019
Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer
Mar 07, 2019
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
Feb 27, 2019
Breckenridge Announces Final Approval of its ANDA for Exemestane Tablets (Aromasin®)
Jan 07, 2019
Syndax Highlights 2019 Clinical and Corporate Outlook
Oct 11, 2017
Upsher-Smith Launches Generic Version Of Aromasin® (Exemestane) Tablets
Oct 05, 2017
Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin